OLD Category: skin disease

High-plex predictive marker discovery for melanoma immunotherapy treated patients using Digital Spatial Profiling

• Toki MI, Merritt CR, Wong PF, Smithy JW, Kluger HM, Syrigos KN, Ong GT, Warren SE, Beechem JM, Rimm DL

Mast cells are mediators of fibrosis and effector cell recruitment in dermal chronic graft-versus-host disease

• Strattan E et al.,

Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial

• Rozeman EA et al.,

Gene expression and promoter methylation of angiogenic and lymphangiogenic factors as prognostic markers in melanoma

• Monteiro AC et al.,

Validation of the GARD™skin Assay for Assessment of Chemical Skin Sensitizers: Ring Trial Results of Predictive Performance and Reproducibility

• Johansson H et al.,

Expression of the (pro)renin receptor and its effect on endothelial cell proliferation in infantile hemangioma

• van Schaijik B et al.,

Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression

• Garcia-Diaz A et al.,

Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy

• Perez-Ruiz E et al.,

Intervention of Inflammatory Monocyte Activity Limits Dermal Fibrosis

• Haub J et al.,

Multiple antigen-engineered DC vaccines with or without IFNα to promote antitumor immunity in melanoma

• Butterfield LH et al.,

Evaluation of in vitro testing strategies for hazard assessment of the skin sensitization potential of real-life” mixtures: the case of henna-based hair coloring products containing p-phenylenediamine.”

• de Ávila RI et al.,

Evaluation of in vitro testing strategies for hazard assessment of the skin sensitization potential of “real-life” mixtures: the case of henna-based hair coloring products containing p-phenylenediamine

• de Ávila RI et al.,